<Part 1: Single ascending dose> Primary objective~To evaluate the safety and tolerability of a single oral dose of ASP3325 in non-elderly, healthy adult Japanese male and female, and Caucasian male subjects~Secondary objectives~To evaluate the pharmacokinetics and pharmacodynamics~To evaluate gender differences in the pharmacokinetics and pharmacodynamics~To evaluate ethnic differences in the pharmacokinetics and pharmacodynamics between Japanese and Caucasians~<Part 2: Multiple ascending dose> Primary objective~To evaluate the safety and tolerability of multiple oral doses of ASP3325 in non-elderly, healthy adult Japanese male and female subjects~Secondary objectives~To evaluate the pharmacokinetics and pharmacodynamics~To evaluate gender differences in the pharmacokinetics and pharmacodynamics~<Part 3: Evaluation of the effect of administration timing> Primary objective~To evaluate the effect of administration timing on the pharmacodynamics of ASP3325 orally administered three times a day at different administration timings of 30 minutes before a meal, during a meal, 30 minutes after a meal, and 2 hours after a meal in non-elderly, healthy adult Japanese male subjects in a crossover design~Secondary objective~To evaluate the safety and pharmacokinetics
The objectives of this study are to evaluate the safety and tolerability of a single and multiple oral dose of ASP3325 and to evaluate the effect of administration timing on the pharmacodynamics of ASP3325 orally administered three times a day.